PTAB statistics

PTAB Trial Statistics as of December 4, 2014

As of December 4, 2014, USPTO records show 2,414 AIA trial petitions filed since September 16, 2012 (2,144 IPR, 262 CBM, 3 PGR, 5 derivation). The Board had instituted trial on 1,044 petitions and denied 492 (68.0% instituted) and had issued 217 final written decisions. In fiscal year 2015 to that date, 333 petitions were filed.

Key Facts

As of
December 4, 2014
Fiscal year
FY2015
Petitions filed (cumulative)
2,414
Institution rate (cumulative)
68.0%
Petitions filed (FY2015 to date)
333
Data retrieved
October 31, 2026
On this page
  1. Cumulative Figures as of December 4, 2014
  2. Fiscal Year 2015 to Date
  3. Change Since November 27, 2014
  4. Trial Types Covered
  5. How These Figures Were Compiled
  6. Related Statistics

This page gives Patent Trial and Appeal Board trial figures as of December 4, 2014, which falls in fiscal year 2015 (October 1, 2014 to September 30, 2015). The cumulative figures run from September 16, 2012, when AIA trials began. The full year is covered on the FY2015 statistics page.

Cumulative Figures as of December 4, 2014

Events from September 16, 2012 to December 4, 2014, by trial type:

MeasureIPRPGRCBMDERTotal
Petitions filed2,144326252,414
Institution decisions: instituted924012001,044
Institution decisions: denied4281603492
Institution rate (by petition)68.3%0.0%66.7%0.0%68.0%
Final written decisions1970200217
Terminations without a final written decisionCount
Settlements186
Adverse judgment0
Dismissed0
Other terminations8

Fiscal Year 2015 to Date

Events from October 1, 2014 to December 4, 2014:

MeasureIPRPGRCBMDERTotal
Petitions filed3031290333
Institution decisions: instituted1850130198
Institution decisions: denied7514080
Institution rate (by petition)71.2%0.0%76.5%—71.2%
Final written decisions4703050
Terminations without a final written decisionCount
Settlements42
Adverse judgment0
Dismissed0
Other terminations0

Change Since November 27, 2014

Between the previous dated page (November 27, 2014) and December 4, 2014, 22 petitions were filed, 15 trials were instituted, 20 petitions were denied institution and 2 final written decisions issued. The cumulative institution rate moved from 68.6% to 68.0%.

Trial Types Covered

2,144 of the 2,414 petitions (88.8%) were for inter partes review, which challenges patent claims on prior-art grounds under 35 U.S.C. chapter 31. The remainder were for covered business method review (262), post-grant review under chapter 32 (3) and derivation proceedings (5). Institution standards differ by proceeding; see the threshold standards.

How These Figures Were Compiled

The figures are counted from USPTO Open Data Portal records retrieved on October 31, 2026, keeping only events dated on or before December 4, 2014: a petition by its filing date, an institution decision by its decision date, and a final written decision or termination by its date. They are a reconstruction from the current records, not the USPTO’s report of that date, and may differ from statistics the USPTO published at the time. Final written decision outcomes are not reported because the records state them for too few decisions. The methodology gives the counting rules in full.

Frequently Asked Questions

How many AIA trial petitions had been filed as of December 4, 2014?

USPTO records show 2,414 petitions filed from September 16, 2012 to December 4, 2014: 2,144 IPR, 262 CBM, 3 PGR and 5 derivation.

What was the PTAB institution rate as of December 4, 2014?

Cumulatively, 68.0% by petition: 1,044 instituted and 492 denied. In FY2015 to that date the rate was 71.2%.

Primary Sources

  1. USPTO Open Data Portal (PTAB trial proceedings and decisions data)
  2. USPTO Patent Trial and Appeal Board statistics
  3. 35 U.S.C. chapter 31 (inter partes review)
  4. 35 U.S.C. chapter 32 (post-grant review)
  5. 37 C.F.R. Part 42 (trial practice before the PTAB)

Educational information; not legal advice. Statutes, rules and USPTO practice change. Confirm against the primary sources and consult a registered patent practitioner before acting. Disclaimer.